Search

The David H. Koch Center for Cancer Care has recently been recognized by a number of industry leaders for its innovative and resilient design, some of the many features that put the 750,000 square foot facility in a class of its own.

… Friday, June 5, 2020 It’s been six months since members of the MSK Boards of Overseers and Managers, hospital leadership, and local elected officials joined together to celebrate the opening of the David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center . Recently, the facility

Couldn’t be at ASCO this year? Read highlights from the first half of the meeting.

… Monday, June 6, 2016 Summary Among the highlights presented at this year’s American Society of Clinical Oncology annual meeting were advances in targeted therapy for small cell lung cancer, immunotherapy for non-small cell lung cancer, and insights into the biology of bladder cancer immunotherapy responders

After years of planning and anticipation, the David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center is scheduled to open in January 2020.

… Friday, December 6, 2019 After years of planning and anticipation, the  David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center is scheduled to open in January 2020.   Located off York Avenue on 74th Street, the David H. Koch Center for Cancer Care at Memorial Sloan Kettering is

Westchester Medical Center today announced the opening of its new 5,300-square-foot outpatient Infusion Center, ushering in a new partnership with Memorial Sloan Kettering Cancer Center, whose staff will provide outpatient cancer care and infusion services.

… Wednesday, February 13, 2013 Westchester Medical Center (WMC) today announced the opening of its new 5,300-square-foot outpatient Infusion Center, ushering in a new partnership with Memorial Sloan Kettering Cancer Center (MSKCC), whose staff will provide outpatient cancer care and infusion services.

Research recently published by MSK scientists suggests that the best way to fight dangerous bacteria may be with other bacteria.

… Tuesday, June 20, 2017 Summary People with cancer are particularly susceptible to infections because treatment often damages their immune system. Now research is suggesting that the best way to combat these dangerous infections may be with other, nonharmful bacteria. Highlights Antibiotics are an important

A new study by a team of 12 thoracic surgeons at Memorial Sloan Kettering Cancer Center (MSK), published recently in the Annals of Surgery,([i]) is the first to identify a comprehensive list of clinical factors significantly associated with referring patients with stage 1 NSCLC to SBRT.

… Tuesday, November 5, 2024 Minimally invasive surgery (MIS) and stereotactic body radiotherapy (SBRT) are both used to treat stage 1 non-small cell lung cancer (NSCLC). While MIS remains the standard of care for patients with operable disease, selecting which patients should be referred for SBRT has been

A newly identified group of immunosuppressive cells could provide insight into the effects of immunotherapy drugs.

… Tuesday, June 12, 2018 Summary MSK researchers have identified a new group of immunosuppressive cells that are affected in opposite ways by two common checkpoint inhibitors often given in combination. These cells are easily detectable in the blood and could help doctors make immunotherapy work better

A commentary by members of Memorial Sloan Kettering Cancer Center’s (MSK) Bobst International Center along with members of the Bloomberg New Economy International Cancer Coalition (the “Coalition”) calls for global collaboration to reimagine patient-centric cancer clinical trials. The piece was published in the April 19, 2022, “The Future of Cancer Research” special Focus edition of the journal Nature Medicine.

… Thursday, April 21, 2022 A commentary by members of Memorial Sloan Kettering Cancer Center’s (MSK) Bobst International Center along with members of the Bloomberg New Economy International Cancer Coalition (the “Coalition”) calls for global collaboration to reimagine patient-centric cancer clinical trials

After graduate student Irene Dimatulac was diagnosed with osteosarcoma in her knee, treatment at MSK — and support from MSK’s Adolescent and Young Adult Program — allowed her to get back to her life.

… Thursday, July 29, 2021 It was Valentine’s Day in 2020 when Irene Dimatulac learned she had bone cancer in her left knee. “I’d been having pain for a few years, but it finally got to the point of not being manageable,” says the avid rock climber and speech pathology graduate student, who was 25 years

Después de que a la estudiante de posgrado Irene Dimatulac le diagnosticaran osteosarcoma en la rodilla, el tratamiento en MSK —y el apoyo del Programa para Adolescentes y Adultos Jóvenes de MSK— le permitieron volver a su vida.

… Thursday, July 29, 2021 Irene Dimatulac se enteró de que tenía cáncer de hueso en la rodilla izquierda el Día de San Valentín de 2020. “Había tenido dolor durante unos años, pero finalmente llegó al punto de que sentía que no lo podía manejar”, dice la escaladora entusiasta y estudiante de posgrado en